ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO948

Senescent Lymphocyte Subsets Exhibit an Unexpected Advantageous Effect in the Response Against SARS-CoV-2 Vaccination in Dialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Lioulios, Georgios, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Fylaktou, Asimina, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Tsouchnikas, Ioannis, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Giamalis, Panagiotis, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Xochelli, Aliki, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Christodoulou, Michalis, Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Papagianni, Aikaterini A., Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
  • Stangou, Maria J., Geniko Nosokomeio Thessalonikes Ippokrateio, Thessaloniki, Greece
Background

Vaccination against SARS-CoV-2 is a potent preventive tool against Covid-19. However, response to vaccination vary depending on comorbidities. This study evaluates clinical and immunological factors affecting humoral response of End-Stage Renal Disease(ESRD) patients to BNT162b2 Vaccine.

Methods

Humoral immunity was evaluated in 54 ESRD patients, by serum levels of anti-receptor-binding-domain (RBD) and neutralizing antibodies (Nab), measured by CLIA, 30 (T1), 60 (T2) and 120 (T3) days, after the second vaccine dose. Results were correlated to baseline patients’ T and B-lymphocyte subpopulations as determined by flow cytometry.

Results

Proportion of seroconverted patients based on Nab titer was diminished from 83.3%(Τ1) to 53.7%(Τ3), in three months. Age was negatively correlated to Nab at T1 and T2 (Τ1:R=-0.334, p=0.027, Τ2:R=-0.344, p=0.022). Patients on hemodiafiltration had higher Nab titers at T3. Presence of diabetes was associated with lower response rate, as 9/11 diabetics compared to 16/43 non-diabetics lost seroconversion at T3.

Univariate analysis revealed a strong positive correlation of naïve CD4 T-lymphocyte population with RBD at T1(R2=0.199, p=0.015) and with Nab titer at T3(R2=0.645, p<0.001), while no association was shown with naïve CD8 T-lymphocytes. Nab titers at T3 were significantly correlated with late differentiated CD4 T-lymphocytes(R2=0.56, p<0.001) and EMRA CD8 T-lymphocytes(R2=0.156, p=0.017). Finally, RBD levels had a significant positive correlation with naïve, and negative with memory B-lymphocyte count at T3(R2=0.147, p=0.031, R2=0.159, p=0.039, respectively).

Conclusion

Age, diabetes mellitus and hemodialysis prescription have a strong impact to response to vaccination. T and B-lymphocytes phenotype are major determinants of humoral response potency to COVID vaccination with BNT162b2, in ESRD patients.